louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05664022: Effect of Global Postural Reeducation on Low Back Pain Patients With Lower Cross Syndrome
Official title: Effect of Global Postural Reeducation on Low Back Pain Patients With Lower Cross Syndrome. Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Low Back Pain, Postural
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2022-12-23
Enrollment: 50
Sex: ALL
Minimum age (years): 25
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study will be conducted toinvestigate the effect of Global Postural Re-education on low back pain patients with Lower cross syndrome

Detailed description: Lower cross syndrome is common, with up to 85% of low back pain cases due to long-term postural faults (Lower crossed syndrome) and it has a negative result on our society. Global Postural Re-education (GPR) is an intervention that is used frequently for chronic low pain to improve pain and function. 50 low back pain patients with lower cross syndrome will be assigned randomly into 2 groups, Group A will receive a Global Postural Re-education approach and consists of 15 treatment sessions of Global Postural Re-education approach, performed 2times/week for 1 hour including patient education. Each treatment is individualized for every patient and for his/her pain-related limitation. Each session includes only 2-3 postures to increase the standardization of treatment. Group B will receive the conventional treatment in form of exercise program of (abdominal and pelvic floor strengthening) and (stretching exercise of back and hip flexor muscles) to improve pain and function in chronic low back pain patients

Eligibility criteria: Inclusion Criteria:

* 50 patients.
* Both sexes will be included.
* Patients' age range will be 25 to 40 years old (Esakowitz., 2014).
* Participants will have to meet the criteria for lower crossed syndrome indicating tight hip flexors and erector spinae together with weak glutei and abdominals with low back pain will be presented three months or longer and level of pain intensity more than 3 on VAS.

Exclusion Criteria:

* On other forms of treatment that may interfere with the study including other physical therapy or medication specific to back pain.
* Enrolled in another interventional clinical research trial
* Pregnancy
* Nerve entrapment, bowel or bladder dysfunction and kidney disease.
* Surgery on the back, pelvis or sacrum is indicated or has previously occurred.

Primary outcomes:
measure: anterior pelvic tilting
timeFrame: up to twelve weeks
measure: lumbar lordosis
timeFrame: up to twelve weeks
measure: flexibility of hip flexors muscle
timeFrame: up to twelve weeks
measure: pain severity
timeFrame: up to twelve weeks
measure: function disability
timeFrame: up to twelve weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Damanhūr
country: Egypt
facility: Damanhour teaching hospital
Study officials:
affiliation: Damanhour Teaching Hospital
name: Enas En Kandil
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03286322: Comparison of a Classical Rehabilitation Method and a Specific Rehabilitation Method of the Cervical Spine
Official title: Comparison of a Classical Rehabilitation Method and a Specific Rehabilitation Method of the Cervical Spine to Improve Balance in Elderly Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Loss of Balance
Lead sponsor: Centre Hospitalier Universitaire de Nice
Sponsor class: OTHER
First posted: 2017-09-18
Enrollment: 86
Sex: ALL
Minimum age (years): 75
Standard ages: OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: In more than 90% of cases, victims of fall are elderly people over 65. Nearly the third of those people fall at least 1 time by year. The incidence substantially increases for people over 80 and women are at higher risk than men.

The value of balance rehabilitation no longer needs to be demonstrated in Gerontology. Nevertheless, a more specific therapy based on the aged-related cervical problems seems to be essential. Indeed, those problems are numerous (arthrosis-like pains, joint stiffness, muscular contractures...) and often lessen vestibular and/or proprioceptive afferents. The cervical spine is a link between different systems which regulate balance, as the visual, vestibular and cervical systems (muscular, articular afferents...), and this role is key to balance control. Indeed, the cervical spine owns an exceptional function thanks to Ruffinian corpuscles, muscle and neurotendinal spindles.

Many studies point up the importance of the relation between balance, cervical spine and vestibular system, and others between tissue changes and postural adaptations in elderly people. Nevertheless, the take into consideration of all these data and their impacts in rehabilitation has not been reported yet.

This brings us to question the added-value of a cervical mobility management in balance rehabilitation in Gerontology.


Eligibility criteria: Inclusion Criteria:

* Patients over 75 hospitalized in rehabilitation department and long-term unit of Cimiez Hospital
* With MMSE \> 20
* In need of balance rehabilitation
* Who can stand Bipodal position for \>1 minute
* Who can walk for more than 10 meters without walking aid
* Having signed an informed consent
* Affiliated to a health insurance plan

Exclusion Criteria:

* Motor neurological deficit, specific vestibular pathologies
* Patient hospitalized for traumatological pathology or who has been hospitalized for traumatological pathology within 3 months
* Vulnerable people: adults under guardianship, deprived of freedom

Primary outcomes:
measure: Percentage decrease of the wobbling surface eyes open on steady ground, on a posturology platform
timeFrame: at 3 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Nice
country: France
facility: CHU de Nice
Study officials:
affiliation: Centre Hospitalier Universitaire de Nice
name: Sébastien GONFRIER, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00718822: Outcome of Embryo Culture at Two Oxygen Tensions
Official title: Does Reduced Oxygen Tension in Embryo Culture Influence Clinical Outcome of ICSI Cycles? A Prospective Randomized Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Embryo Development
Keywords: clinical outcome
ICSI cycles
low oxygen
poor responders
pregnancy rate
prospective randomized study
Lead sponsor: University Medical Centre Maribor
Sponsor class: OTHER
Collaborators: name: Slovenian Research Agency
First posted: 2008-07-21
Enrollment: 647
Sex: FEMALE
Minimum age (years): 22
Maximum age (years): 44
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to assess whether reduced oxygen tension in embryo culture has any effect on clinical outcome.


Eligibility criteria: Inclusion Criteria:

* stimulated Intra Cytoplasmic Sperm Injection (ICSI) cycle

Exclusion Criteria:

* less than one mature (metaphase II) oocyte at the time of denudation

Primary outcomes:
measure: Ongoing pregnancy rate per cycle
timeFrame: 10-11 weeks after embryo transfer
Secondary outcomes:
measure: clinical pregnancy rate, implantation rate, early pregnancy loss, fertilization rate, embryo quality
Other outcomes:
Locations:
city: Maribor
country: Slovenia
facility: University Clinical Centre Maribor
Study officials:
affiliation: University Medical Centre Maribor
name: Veljko Vlaisavljević, Prof.
role: STUDY_CHAIR
References:
Clinical trial NCT02334722: 1 Week Versus 6 Weeks of Levetiracetam in Surgical Brain Tumor Patients
Official title: A Shortened Antiepileptic Drug (AED) Course in Surgical Brain Tumor Patients: A Randomized Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Brain Neoplasms
Brain Cancer
Brain Tumors
Cancer of the Brain
Cancer of Brain
Seizure
Lead sponsor: University of Florida
Sponsor class: OTHER
First posted: 2015-01-08
Enrollment: 81
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to see if there are any differences in patient reported neurotoxicity between patients who receive Levetiracetam tablets for one week after surgery to remove a brain tumor versus those who receive Levetiracetam tablets for six weeks after surgery. Specifically, we will see if one group has less side effects than the other, and whether or not one group has more seizures than the other.

Detailed description: Because seizures are one of the leading neurologic complications in brain tumor patients, neurosurgeons prescribe antiepileptic drugs (AEDs) to help prevent them. Although the American Academy of Neurology (AAN) guidelines recommend that AEDs be stopped after the first post-operative week in patients without seizures, there is no standard length of treatment and some patients may stay on AEDs indefinitely.

In an attempt to develop clinical guidelines for AED use in post-operative brain tumor patients, we will try to determine if taking levetiracetam for 1 week results in less neurotoxicity than taking it for 6 weeks.

Eligibility criteria: Inclusion Criteria:

* Adult (\>18 years of age and older) patients who have or will have undergone surgical resection or biopsy of a supratentorial brain tumor and are able to consent for themselves.
* Able to be randomized prior to or up to 48 hours after surgery.

Exclusion Criteria:

* No known history of seizure activity.
* Pregnant or breastfeeding.
* Renal dysfunction (CrCl \< 30ml/min).
* Beck's Depression Inventory (BDI) ≥14
* Allergy to levetiracetam.

Primary outcomes:
measure: Change in Neurotoxicity Scale Scores
timeFrame: Baseline to 6 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Gainesville
country: United States
facility: University of Florida
state: Florida
Study officials:
affiliation: University of Florida
name: Maryam Rahman, MS, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06636422: Post-marketing Safety and Efficacy Surveillance of Motherwort Injection
Official title: Post-marketing Safety and Efficacy Surveillance of Motherwort Injection : a Registry Study
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Bleeding
Real-world Study
Adverse Events
Keywords: Adverse events
Motherwort injection
bleeding
real-world study
Post-abortion hemorrhage
Uterine retraction
Lead sponsor: China Academy of Chinese Medical Sciences
Sponsor class: OTHER
First posted: 2024-10-10
Enrollment: 20000
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients from designated medical institutions (departments) who meet the clinical indications for the use of motherwort injection as determined by a physician, voluntarily participate in this study, and fulfill ethical requirements.

Brief summary: This study aims to provide evidence concerning the safety and efficacy of motherwort injection in real-world settings.


Eligibility criteria: Inclusion Criteria:

* Meet the clinical indications for the use of motherwort injection
* Voluntarily participate in this study
* Fulfill ethical requirements.

Exclusion Criteria:

* None

Primary outcomes:
measure: The type and incidence of adverse events.
timeFrame: From the initiation of medication to 7 days after cessation.
measure: Bleeding control.
timeFrame: From the commencement of the surgery to the end of bleeding event, assessed up to 1 year.
measure: The incidence of postpartum hemorrhage.
timeFrame: From the completion of the surgery to 24 hours following the delivery of the fetus.
measure: The post-abortion recovery.
timeFrame: From the completion of the abortion to the subsequent onset of menstruation, assessed up to 1 year.
measure: The incidence of post-abortion bleeding.
timeFrame: From the completion of the abortion to the end of bleeding event.
Secondary outcomes:
measure: The types and incidence of adverse reactions.
timeFrame: From the initiation of medication to 7 days after cessation.
measure: Analysis of factors associated with adverse reactions.
timeFrame: From the initiation of medication to 7 days after cessation.
measure: The menstrual adjustment.
timeFrame: From the initiation of medication to menstruation returns to normal or the treatment is completed, whichever came first, assessed up to 1 year.
measure: The uterine retraction status.
timeFrame: From the the postpartum to the end of bleeding event, assessed up to 1 year.
Other outcomes:
measure: The assessment of treatment satisfaction.
timeFrame: From the initiation of medication to 7 days after cessation.
Locations:
Study officials:
References:
Clinical trial NCT04375839: Zirconia Vs Titanium Implants in Deficient Ridges
Official title: Zirconia Vs Titanium Implants in Horizontally Deficient Ridges - A Clinical and Radiographic Outcome-Based Study
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Alveolar Bone Loss
Periodontitis
Lead sponsor: SVS Institute of Dental Sciences
Sponsor class: OTHER
First posted: 2020-05-05
Enrollment: 24
Sex: ALL
Minimum age (years): 25
Maximum age (years): 44
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The aim of this study is to evaluate clinically and radiographically soft tissue around single-implant crowns and peri-implant bone resorption respectively by using zirconia implants or titanium implants in horizontally deficient partially edentulous ridges.

Detailed description: Experimental: Main treatment group Zirconia implants will be placed in a prosthetically guided position in horizontally deficient ridges in main treatment group.

Active Comparator: Control group Titanium implants will be placed in a prosthetically guided position in horizontally deficient ridges in control group.

Eligibility criteria: Inclusion Criteria: Based on the classification of alveolar ridge width given by Tolstunov, subjects with

* partially edentulous (2/3 teeth missing)
* systemically healthy subjects within the age group of 25-44 years
* Class III ridges characterized by moderate i.e., 4-6mm of alveolar ridge width will be included.

Exclusion Criteria:

* Medically compromised patients

  -. Subjects who underwent radiotherapy or chemotherapy and with
* Habit of smoking, tobacco and alcohol abuse
* Subjects with active periodontal disease to residual dentition and lack of oral hygiene will be excluded from this study.

Primary outcomes:
measure: Evaluation of the soft tissue around single implant crowns
timeFrame: Baseline to 6 months
measure: Peri-implant bone resorption
timeFrame: Baseline to 6 months
Secondary outcomes:
measure: Implant survival rate
timeFrame: Baseline to 6 months
Other outcomes:
Locations:
city: Hyderabad
country: India
facility: SVS Institute of Dental Sciences
state: Telangana
Study officials:
References:
Clinical trial NCT04028739: Theracurmin vs Curcumin Bioavailability Study
Official title: A Randomized, Open-label, Cross-over, Single Administration Study to Compare Bioavailability of Curcumin in Health Adults
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Bioavailability
Lead sponsor: Handok Inc.
Sponsor class: INDUSTRY
First posted: 2019-07-23
Enrollment: 24
Sex: ALL
Minimum age (years): 19
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: BASIC_SCIENCE

Brief summary: A randomized, open-label, cross-over, single administration study to compare bioavailability of curcumin in health adults

Detailed description: * Randomization, Open-label, 3-period, 6-sequence, Crossover, Single
* Drug-free inverval : more than 7 days
* Sampling time : 0,0.5,1,1.5,2,3,4,6,8,12h

Eligibility criteria: Inclusion Criteria:

1. Healthy adult 19 to 60 years
2. BMI 18.0\~30.0kg/m2 at screening
3. Subject who was given, and fully understood, the information about the study, and has provided voluntary written informed consent to participate in the study and agreed to comply with the study requirements.

Exclusion Criteria

1. A person with clinically significant disease corresponding to cardiovascular, respiratory, liver, kidney, digestive system, blood/tumor system, endocrine system, immune system, neuropsychiatry or who has a history within the last 6 months.
2. A person with a history of gastrointestinal disease or surgery (except for simple cecal surgery or hernia surgery) that may affect the absorption of food for clinical research.
3. Persons who have an irritable reaction to foods containing turmeric or other drugs and food.
4. Those who took medicines within 7 days before the first intake of food for clinical research.
5. Food for Clinical Research If you have consumed foods containing turmeric (eg, radishes, curry) within 7 days before the first intake of food, or you can't consume until the day of intake of food for the last clinical study.
6. Those who have participated in other clinical studies within 90 days prior to the first intake of food for clinical research.
7. Women who are pregnant or lactating during screening, or who plan to become pregnant during clinical research. A person who is deemed unsuitable for participating in this clinical study because of other reasons.

Primary outcomes:
measure: Cmax
timeFrame: 12hours
measure: AUC
timeFrame: 12hours
Secondary outcomes:
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Korea Kuro Hospital
Study officials:
affiliation: Korea University Guro Hospital
name: Hyewon Chung
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02061839: Prevention of Melasma Relapse During Summertime
Official title: Prevention of Melasma Relapse During Summertime
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Melasma
Lead sponsor: Centre de Pharmacologie Clinique Applique a la Dermatologie
Sponsor class: OTHER
Collaborators: name: BIODERMA
First posted: 2014-02-13
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Main objective is to show that a photoprotective sunscreen having a protection against the visible light is more effective than a sunscreen having the same UVA AND UVB protection but with a low (weak) protection against the visible, to prevent the relapses of the melasma during the summertime.

Detailed description: 40 melasma affected women will be included and randomized in two parallel groups (one group protected by a UVA+UVB+visible extended sunscreen and one group group protected by a UVA+UVB sunscreen).

There will be 3 visits: Baseline, T2.5months and T5months (final visit).

Products application frequency: twice daily(morning and afternoon) and additional applications every 2 hours in case of solar exposure.

Main evaluation criterion: the MASI score assessed from standardized photographs (system VISIA, Canfield Scientific, USA) at Baseline, middle and end of study.

Eligibility criteria: Inclusion Criteria:

* Melasma

Exclusion Criteria:

* Other pigmentary disorders associated (including PIH)

Primary outcomes:
measure: Comparison between MASI scores before prevention treatment and after 6 months
timeFrame: 6 months
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT02241239: A Comparison of the Estimates of Fuwai and Reynolds Risk Model
Official title: A Comparison of the Estimates of Fuwai and Reynolds Risk Model
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Coronary Heart Disease and Stroke
Lead sponsor: Wuhan Asia Heart Hospital
Sponsor class: OTHER
First posted: 2014-09-16
Enrollment: 500
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: adults without coronary heart disease

Brief summary: There are many risk prediction models. And their estimates are different. This study aimed to investigate the differences between the estimates of Fuwai and Reynolds risk model in Chinese, and investigate the reason for the differences.

Detailed description: The participants will examined for cardiovascular risk factors, and their cardiovascular risks will be calculated based on the values of the risk factors using cardiovascular risk models. The estimates of different risk models will be compared, and the levels of traditional risk factors will be adjusted in order to evaluate the impacts of uncommon risk factors such as social and genetic risk factors.

Eligibility criteria: Inclusion Criteria: adults -

Exclusion Criteria: with coronary heart disease

-

Primary outcomes:
measure: cardiovascular risk
timeFrame: 1 day
Secondary outcomes:
Other outcomes:
Locations:
city: Wuhan
country: China
facility: Wuhan Asia Heart Hospital
state: Hubei
city: Wuhan
country: China
facility: Wuhan Asia Heart Hospital
Study officials:
affiliation: Wuhan Asia Heart Hospital
name: Youping Chen, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05333939: Moringa Supplementation for Improved Milk Output
Official title: Investigating the Effect of Moringa Oleifera Leaf Powder on Breastmilk Quantity and Quality: a Double Blinded Randomized Placebo-controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Breastfeeding
Keywords: maternal and child health
Lead sponsor: University of Kentucky
Sponsor class: OTHER
Collaborators: name: University of Idaho
First posted: 2022-04-19
Enrollment: 41
Sex: ALL
Minimum age (years): 0
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: placebo controlled randomized controlled trial
Primary purpose: TREATMENT

Brief summary: The overall objective is to obtain preliminary data on the effect of Moringa oleifera leaf supplementation (moringa) at 4g daily for four weeks compared to placebo to improve human milk quantity and quality and infant health. Hypothesis: Four grams of moringa daily by mouth compared to placebo will increase breastmilk output and percent of mother's own milk consumed by infant.


Eligibility criteria: Mom

YES:

* willing to breastfeed or pump for one week
* willing to complete study activities (at minimum measure 24 hour pumped volume at start and end of capsules, take capsules daily, and answer questions)
* has access to breastpump (in hospital and/or home)
* English speaking
* 18 years or older
* Gave birth between 2-6 weeks prior to study start

NO:

* taking metoclopramide (trade name Reglan) currently or within 2 weeks of enrollment
* taking moringa regularly or within 2 weeks of enrollment
* breast surgery (amplification, reduction, or other)
* breast condition: Insufficient Glandular tissue
* unprescribed or street drug use at any point in pregnancy, or enrolled in rehab program or receiving addiction therapy
* refuses to take 4 capsules twice daily within 2 days of study start
* wishes to withdraw within 2 days of study start

Infant

YES:

* 28-36 and 7 weeks gestation (ie 37 weeks is too old)
* 2-6 weeks old
* singleton birth

NO:

· any condition where breastmilk is clinically contraindicated

Primary outcomes:
measure: Milk output
timeFrame: 7 days
Secondary outcomes:
measure: % mother's own milk consumed by infant
timeFrame: 7 days
Other outcomes:
Locations:
city: Lexington
country: United States
facility: University of Kentucky
state: Kentucky
Study officials:
affiliation: University of Kentucky
name: Suzanna Attia, MD
role: PRINCIPAL_INVESTIGATOR
References: